Established in 2016, Coherent Biopharma’s proprietary bi-targeting XDC technology platform includes BESTTM Platform, C-PROTAC Platform and Chronic Diseases Platform. With the possibility to actively and cell/tissue specifically deliver any bioactive molecule, bi-targeting XDC technology of CBP has the potential to overcome the undruggability obstacle of a variety of molecules with high bioactivity, thus to Drug the Undruggable, and pioneer a new pathway of drug development.
Company Details
- Employees
- 10
- Founded
- 2016
- Address
- Suzhou, China, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.coherentbio.com
- HQ
- Suzhou, China
- Competitors
- COHERENT BIOPHARMA (SUZHOU) CO., LTD., FARVER INVESTMENT MANAGEMENT, BioCity Biopharma, Far East Investment Management (Hong Kong) Limited, Fourier Capital Management Limited, Canaan Investment Management Limited, Bristol Myers Squibb, NeuShen Therapeutics, Longevity Investment Management Hong Kong Limited, GeneQuantum Healthcare (Suzhou) Co., Ltd.
Coherent Biopharma Questions
Coherent Biopharma's website is https://www.coherentbio.com
Coherent Biopharma's LinkedIn profile is https://www.linkedin.com/company/coherentbio
Coherent Biopharma has
10 employees.
View email and phone details for 10
employees at Coherent Biopharma.
Coherent Biopharma's industry is
Biotechnology Research
Coherent Biopharma's top competitors are
Coherent Biopharma (Suzhou) Co., Ltd.,
Farver Investment Management,
Biocity Biopharma,
Far East Investment Management (Hong Kong) Limited,
Fourier Capital Management Limited,
Canaan Investment Management Limited,
Bristol Myers Squibb,
Neushen Therapeutics,
Longevity Investment Management Hong Kong Limited,
Genequantum Healthcare (Suzhou) Co., Ltd.
Coherent Biopharma's categories are Biotechnology Research
Coherent Biopharma's founding year is 2016
